Literature DB >> 31967035

METASTATIC HÜRTHLE CELL CARCINOMA PRESENTING WITH LOW FREE THYROXINE, SEVERE HYPERCALCEMIA AND SPURIOUS GROWTH HORMONE PRODUCTION.

S Rehman, K K Dhatariya.   

Abstract

OBJECTIVE: Hürthle cell tumors constitute about 5% of thyroid neoplasms. They have malignant potential, behaving very aggressively compared to other differentiated thyroid cancers. The objective of this case report is to describe a case of a Hürthle cell carcinoma with a single large metastasis in the liver presenting almost 17 years after hemithyroidectomy. We highlight the difficulties in making a histologic diagnosis and the unpredictable nature of this cancer.
METHODS: The patient history and biochemistry were detailed. Thyroid function tests analyzed on multiple platforms (single-photon emission computed tomography, dynamic magnetic resonance imaging, technetium-99m bone scan, and radioactive iodine) were used to aid biochemical and radiologic diagnosis.
RESULTS: The patient's thyroid function test showed persistently low free thyroxine concentrations with normal thyroid stimulating hormone and free triiodothyronine, suggesting rapid deiodination in the context of a large liver lesion. Radiologic and morphologic appearances of the liver lesion led to an initial misdiagnosis of primary hepato-cellular carcinoma, revised to metastatic Hürthle cell carcinoma after positive immunochemistry. Nonparathyroid hormone-related intractable hypercalcemia of malignancy with an unusual pattern of elevated 1,25-dihydroxyvitamin D and raised fibroblast growth factor 23 concentrations culminated in his demise.
CONCLUSIONS: In Hürthle cell carcinomas treated with partial thyroidectomy, subsequent abnormal thyroid functions tests may herald a more sinister underlying diagnosis. The management of Hürthle cell carcinoma relies heavily on the initial histology results. Histologic diagnosis should be sought earlier in abnormal and suspicious distant masses. Malignant hypercalcemia poses a great challenge in delayed presentations and can prove resistant to conventional treatments.
Copyright © 2019 AACE.

Entities:  

Year:  2019        PMID: 31967035      PMCID: PMC6876938          DOI: 10.4158/ACCR-2018-0440

Source DB:  PubMed          Journal:  AACE Clin Case Rep        ISSN: 2376-0605


  30 in total

1.  Hurthle cell carcinoma: a population-level analysis of 3311 patients.

Authors:  Paolo Goffredo; Sanziana A Roman; Julie A Sosa
Journal:  Cancer       Date:  2012-08-14       Impact factor: 6.860

2.  Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid.

Authors:  A R Shaha; J P Shah; T R Loree
Journal:  Am J Surg       Date:  1996-12       Impact factor: 2.565

3.  Transcriptional control of the forkhead thyroid transcription factor TTF-2 by thyrotropin, insulin, and insulin-like growth factor I.

Authors:  L Ortiz; M Zannini; R Di Lauro; P Santisteban
Journal:  J Biol Chem       Date:  1997-09-12       Impact factor: 5.157

4.  In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial.

Authors:  Irene Virgolini; Keith Britton; John Buscombe; Roy Moncayo; Giovanni Paganelli; Pietro Riva
Journal:  Semin Nucl Med       Date:  2002-04       Impact factor: 4.446

5.  Overexpression of type 2 iodothyronine deiodinase in follicular carcinoma as a cause of low circulating free thyroxine levels.

Authors:  B W Kim; G H Daniels; B J Harrison; A Price; J W Harney; P R Larsen; A P Weetman
Journal:  J Clin Endocrinol Metab       Date:  2003-02       Impact factor: 5.958

6.  Hypercalcaemia caused by a carcinoid tumour.

Authors:  M M Brzozowska; L Wolmarans; J V Conaglen
Journal:  Intern Med J       Date:  2009-06       Impact factor: 2.048

7.  3,5,3'-Triiodothyronine thyrotoxicosis due to increased conversion of administered levothyroxine in patients with massive metastatic follicular thyroid carcinoma.

Authors:  Akira Miyauchi; Yuuki Takamura; Yasuhiro Ito; Akihiro Miya; Kaoru Kobayashi; Fumio Matsuzuka; Nobuyuki Amino; Nagaoki Toyoda; Emiko Nomura; Mitsushige Nishikawa
Journal:  J Clin Endocrinol Metab       Date:  2008-04-08       Impact factor: 5.958

Review 8.  Hürthle cell carcinoma: current perspectives.

Authors:  Sara Ahmadi; Michael Stang; Xiaoyin Sara Jiang; Julie Ann Sosa
Journal:  Onco Targets Ther       Date:  2016-11-07       Impact factor: 4.147

9.  Isolated Liver Metastasis in Hürthle Cell Thyroid Cancer Treated with Microwave Ablation.

Authors:  Konstantinos Segkos; Carl Schmidt; Fadi Nabhan
Journal:  Case Rep Endocrinol       Date:  2017-01-09

10.  Indium-111-labelled octreotide scintigraphy in the diagnosis and management of non-iodine avid metastatic carcinoma of the thyroid.

Authors:  J A Christian; G J R Cook; C Harmer
Journal:  Br J Cancer       Date:  2003-07-21       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.